Pergolide legal action
Ing 30 patients who reported dozing off while driving total of 21 420 [5%] ; . Demographic characteristics of these patients, such as mean SD ; age 62.1 [10.4] years ; , Hoehn and Yahr score 2.2 [0.7] ; , Schwab and England "on" score 86.9 [9.5] ; , MMSE 29.2 [0.8] ; , and disease duration 8.6 [6.4] years ; , did not differ significantly from the other drivers Wilks 0.95; F10, 346 1.73; P .07 ; see Table 1 for data on all patients and drivers ; . These events occurred prior to the diagnosis of PD in the patients, leaving 16 of 420 drivers 3.8% ; with sudden onset of sleep while driving since the onset of PD. Eighteen of the 21 also experienced spells of dozing that were not sudden. Only 3 of the 21 with sudden onset of sleep claimed not to have experienced associated preceding drowsiness or other warning signs. These 3 patients' questionnaires are reviewed in detail below. All attributed the events to an alteration in their medication. Only 2 patients recalled any blank spells while driving version 3 of the questionnaire ; . Case 1 was a 66-year-old woman with a 2-year history of PD and an ESS score of 14. At the time of the questionnaire she was taking pramipexole 3 mg d ; and pergolide 1.5 mg d ; . The sudden onset of sleep episodes had occurred in the past and not while she was taking her current medication. Previously, while taking ropinirole unknown dose ; for 12 months, she had 2 spells of sudden onset of sleep. She provided a history of frequently talking in her sleep and acting out her dreams, but denied any other symptoms of a sleep disorder at the time of the questionnaire. Case 2 was a 49-year-old man with a 4-year history of PD and an ESS score of 10. The patient was taking levodopa 1000 mg d ; and pergolide 3 mg d ; at the time of the questionnaire. He admitted to a history of 72 episodes over a 6-month period of suddenly falling asleep at the wheel an average of 2-3 episodes per week ; . The spells were attributed to daytime fatigue secondary to insomnia induced by selegiline, which he had been taking previously. The problem resolved when selegiline was discontinued. His other PD medication was un!
Gilbert et al. randomized 56 children and adolescents with Tourette's syndrome or chronic motor tics to pergolide or placebo. Pergolide reduced tics and ADHD symptoms without causing weight gain or sedation. These results corroborate those obtained in smaller studies of dopaminergic medications for tic suppression.
Evidence alone is of little value without a demonstration of its significance to the employer's alleged discriminatory motive. Id.; Keller, 130 F.3d at 1112. B. Failure to Promote Claim A failure to promote claim is analogous to a claim of failure to hire. Barber v. CSX Distribution Services, 68 F.3d 694, 698 3d Cir. 1995 ; . In order to establish a prima facie case for failure to hire or promote based on sex discrimination, a plaintiff must show "that 1 ; [she] belongs to the protected class, 2 ; that [she] applied for and was qualified for the job, 3 ; that despite [her] qualifications [she] was rejected, and 4 ; that the employer either ultimately filled the position with someone [of the opposite sex] or continued to seek applicants from among those having plaintiff's qualifications." Id. quoting Fowle v. C & C Cola, 868 F.2d 59, 61 3d Cir. 1989 . With respect to the last requirement for a prima facie case, the United States Court of Appeals for the Third Circuit requires that an employee show that the failure to promote occurred "under circumstances which give rise to an inference of unlawful discrimination." Pivirotto v. Innovative Systems, Inc., 191 F.3d 344, 357 3d Cir. 1999 ; . The last requirement in that context necessitates a focus on whether there were circumstances in this case that give "rise to an inference of unlawful discrimination." Id. At the prima facie stage, the court views plaintiff's qualifications objectively, examining whether a plaintiff has the experience and education necessary to be a viable candidate for the position at issue. See Sempier v. Johnson & Higgins, 45 F.3d 724, 729 3d Cir.1995 Kepple v GPU, Inc., 2 F.Supp.2d 730, 741 W.D.Pa 1998 ; . The requisite objective criteria regarding experience and education for a particular job are established by the employer. Kepple v GPU.
Buy pergolide
DISCUSSION: Achromobacter xylosoxidans is a catalase and oxidase positive, motile, gram-negative rod that oxidizes xylose and glucose. A wide variety of infections with this organism have been reported in the immunecompromised host. The most common type of infection appears to be catheter related bacteremia although pneumonia, endocarditis, meningitis, endopthalmitis and septic shock caused by this organism have been described 1 ; . The reported case fatality rate in adults with A.xylosoxidans infection is 30% and in infants as high as 80% 2 ; . There have been 3 reported liver abscesses 3 ; caused by this organism but to our knowledge no documented case of lung abscess has yet been reported. At this time there are no established treatment recommendations for cavitary pulmonary parenchymal disease caused by this organism although long term carbapenems and search and removal of possible source such as indwelling vascular access catheters appears to be effective. REFERENCE: - 1. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer 19892003 ; .Aisenberg G, Rolston KV, Safdar A. Cancer. 2004 Nov 1; 101 9 ; : 213440. 2. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Clin Infect Dis. 1996 Sep; 23 3 ; : 56976. 3. A novel bacterium Achromobacter xylosoxidans as a cause of liver abscess: three case reports. Asano K, Tada S, Matsumoto T, Miyase S, Kamio T, Sakurai K, Iida M. J Hepatol. 2005 Aug; 43 2 ; : 3625.
12 Gupta BN: Teratoma in a chicken Gallus domesticus ; . Avian Dis 20: 762768, 1976 Hibbs CM, Schoneweis D, Leipold HW: Teratomas in two calves. J Vet Res 29: 19811984, 1968 Homer BL, Riggs MW: Cranial teratomas in two domestic ducks Anas platyrhychos domesticus ; . Avian Dis 35: 994998, 1991 Ladds PW, Russell P, Foster RA: Adrenal teratoma in an ox. Aust Vet J 67: 464465, 1990 Lam KY, Lo CY: Teratoma in the region of the adrenal gland: a unique entity masquerading as lipomatous adrenal tumor. Surgery 126: 9094, 1999 Li X, Fox JG, Padrid PA: Neoplastic disease in ferrets: 574 cases 19681997 ; . J Vet Med Assoc 212: 1402 1406, Maekawa A, Onodera H, Furuta K, Tanigawa H, Jagaoka T, Todate A, Matsushima Y, Ogiu T: Teratoma of the pituitary gland in a young male rat. J Comp Pathol 100: 349352, 1989 Mason BJ: Temporal teratomata in the horse. Vet Rec 95: 226228, 1974 Mester M, Trajber HJ, Compton CC, deCamargo HS Jr, de Almeida PC, Hoover HC: Cystic teratomas of the pancreas. Arch Surg 125: 12151218, 1990 Ninomiya H: Spontaneous teratoma in a Wistar rat. Jikken Dobotsu 32 3 ; : 145149, 1983 22 Nielsen SW, Kennedy PC: Tumors in Domestic Animals, 3rd ed., JE Moulton ed. ; , pp. 479517. University of California Press, Berkeley, CA, 1990 23 Nielsen SW, Misdorp W, McEntee K: Tumours of the ovary. International histological classification of tumours of the domestic animals. WHO Bull 53: 215230, 1976 Panciera RJ, Slusher SA, Hayes KE: Ovarian teratoma and granulosa cell tumor in two mares. Cornell Vet 81: 4350, 1991 Patnaik AK, Greenlee PG: Canine ovarian neoplasms: a clinicopathologic study of 71 cases, including histology.
Pergolide for equine use
TO THE EDITOR: In his review article, Donald F. Klein, M.D. 1 ; critiqued the work of my colleagues and me in several ways. Dr. Klein asserted that "Gould et al. [2] performed only a MEDLINE database search that was limited to 20 years, from 1974 to March 1994" pp. 12051206 ; . This statement is incorrect. In fact, we also performed a CD-ROM PsycLIT search for the same years, examined secondary references to locate articles, and included studies that were in press at the time of publication that we had knowledge of because of their presentation at national conferences. Dr. Klein argued that three of our 43 studies were "problematic" and should not have been included in the meta-analysis and that another study should have been included. We agree with Dr. Klein that the Black et al. study 3 ; should have been included and are unclear as to why our original MEDLINE search did not capture this study. We also agree with Dr. Klein that the subjects in the study by Charney et al. 4 ; were not properly randomized and should be excluded. Dr. Klein argued that the study by Klosko et al. 5 ; should not be included for several reasons, one of which was that "Since alprazolam is effective in the treatment of panic disorder, this trial lacked assay sensitivity i.e., the ability to detect specific treatment effects ; " p. 1206 ; . Was Dr. Klein saying that a pharmacotherapy study was invalid if it did not replicate previous pharmacotherapy findings? We agree with McNally's comments 6 ; that Dr. Klein's assertions 7 ; about assay sensitivity suffered from circular reasoning: when a manipulation check and an outcome measure are the same, there exists an inherent tautology. Independent criteria are needed to establish assay sensitivity and permax.
1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000; 96: 3343-3356. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990; 247: 1079-1082. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr abl gene of the Philadelphia chromosome. Science. 1990; 247: 824-830. Carella AM, Podesta M, Frassoni F. et al. Collection of "normal" blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant. 1993; 12: 267271. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991; 114: 532-538. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myelogenous leukemia. Blood. 1997; 89: 26232634. Claxton D, Deisseroth A, Talpaz M, et al. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood. 1992; 79: 997-1002. Bergamaschi G, Podesta M, Frassoni F, et al. Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph-negative peripheral stem cells. Br J Haematol. 1994; 87: 867-870. Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 1981; 58: 158-163. Raskind WH, Ferraris AM, Najfeld V, Jacobson RJ, Moohr JW, Fialkow PJ. Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia. 1993; 7: 1163-1167. Spencer A, Granter N. Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation. Exp Hematol. 1999; 27: 1397-1401. Fayad L, Kantarjian H, O'Brien S, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997; 11: 767771. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-652. Delabesse E, Aral S, Kamoun P, Varet B, Turhan AG. Quantitative non-radioactive clonality analysis of human leukemic cells and progenitors using the human androgen receptor AR ; gene. Leukemia. 1995; 9: 1578-1582. Mitterbauer G, Winkler K, Gisslinger H, Geissler K, Lechner K, Mannhalter C. Clonality analysis using X-chromosome inactivation at the human androgen receptor gene Humara ; . Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. J Clin Pathol. 1999; 112: 93-100. Briere J, El Kassar N. Clonality markers in polycythaemia and primary thrombocythaemia. Baillieres Clin Haematol. 1998; 11: 787-801. Nakahara Y, Suzuki H, Ohashi H, et al. Clonality analysis of granulocytes and T lymphocytes in healthy females by the PCR-based HUMARA method. Int J Hematol. 1999; 69: 237-243. El Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood. 1997; 89: 128-134.
Order Pergolide
36 periodicals, reports and journals on the state of human rights in their countries. Human rights have become a form of ethics required by all peoples and nations of the world. It maybe interesting for a student of the evolution of the concept of human rights to look into the different social and historical changes which have had an impact on the enunciation of this concept. Appendix L lists some of the major international instruments which have become the guidelines for human rights enforcement. Furthermore the United Nations have created various mechanisms to reinforce the application of human rights. An example is when the General Assembly of the United Nations formed special committees charged with examining violations of human rights such as the Special Committee Against Apartheid, the Special Committee charged with inquiring about Israeli practices in the occupied territories, and the Special Committee on Decolonization. Indeed almost all human rights conventions have a special committee that looks at implementation of human rights. There is a committee on economic rights, on social and political rights. In addition, the Economic and Social Council, as well as its subsidiary organs, has a special commission which monitors press and information freedom. There is also a Sub-Commission on Prevention of Discrimination and Protection of Minorities. Moreover, the Commission on Human Rights meets every year and prepares recommendations, as well as discussing existing international instruments on human rights. All these mechanisms point to the interrelationships that exist between the different values which form human rights and their continuous appraisal and adaptation to correct negative situations that emerge on the global scene. Indeed, all the aforementioned mechanisms, conventions and declarations point out that human rights are a universal value. This commission is a special organ, consisting of rapporteurs who submit an annual report to the Commission indicating violations of Human Rights in the world. A number of procedures permit the possibility of receiving every year petitions against Human Rights violations from individuals or groups, and the international procedure is known as procedure no. 10503. However, to further understand the concept of human rights itself, one has to first look at it as value- concept which embodies human dignity. Human dignity is a complex concept consisting of many values that have to be present in order that a human being feels that his dignity is secured. Thus the need for a holistic approach and framework to the understanding of human rights. The right to development is clearly indicated in the Universal Declaration of Human Rights see Appendix B ; . Many have raised the issue of individual as opposed to group rights, A holistic approach to human rights ensures both rights within societies for people, and at a universal level, Economic equity within a State and between States points out to the importance of satisfying and securing the needs of peoples. A sustaining and sustainable environment links development of a community, a group or an individual with their environment. An individual, conscious of his own dignity and his own rights, should, through civic education, care for similar rights for his neighbour, community or nation. For human rights are inseparable and apply equally to both individuals and groups. In addition, the rights of persons belonging to vulnerable groups were endorsed in the World Conference on Human Rights see Appendix B ; ". At this conference, it was reaffirmed that all human rights are indivisible and there is no priority of one human rights over the other. Effectively, the Universal Declaration of Human Rights and its political and social covenants have become a bill of rights binding on all States. How, then, can we promote and safeguard human rights for individuals and groups in societies in which they presently live and which will provide the basis for a sustainable peace? One measure which may enhance human rights is the creation of a parliamentary commission that observes violations of human rights or an independent and perphenazine.
Pergolide structure
In this study we demonstrated for the first time the expression of Smac DIABLO in mouse oocytes and preimplantation embryos. Smac DIABLO mRNA and protein were expressed throughout the developmental stages of preimplantation embryos and in oocytes. Both Smac DIABLO and cytochrome c were localized consistently in the mitochondria of normal embryos. In fragmented embryos or embryos in which apoptotis was induced by staurosporine, translocation of the Smac DIABLO from mitochondria into the cytosol was observed by immunohistochemistry. Apoptosis is mainly orchestrated by a family of aspartate-specific cysteine proteases known as caspases. Caspases are generally divided into two categories, the initiator caspases, which include.
Figure 2. The effect of age on survival. There is no statistically significant differences in survival of patients 40 years, 40-50 years, and 50 years p 0.55 and phenazopyridine.
The mortality rate in hospitals, from severe malnutrition, has not changed in about 40 years at between about 20--40%53, despite the fact that under refugee camp conditions mortality rates of 5-10% are achieved54. Why should this be? First, the concept that kwashiorkor is due to protein deficiency has led to diversion of effort and criticism of the research that is conducted55. Secondly, the protein deficiency concept has led to treatment with high protein diets. At the end of the war, the POWs were initially treated with protein hydrolysates and mortality was very high56. This experience was not applied to the disease in childhood. Several abnormal amino-acid metabolites are excreted in kwashiorkor57"60. These metabolites are similar to those found in inborn errors of metabolism and come from an acquired loss of the enzymes of the catabolic pathways61'62. To give such a patient a high-protein diet, before the enzymatic machinery has recovered, is against all experience in treating inborn errors of metabolism. Initially, Collins63 treated adults with kwashiorkor in the Somalian famine of 1992 93 with the standard high protein diets available. When he switched to a low protein diet, similar to that used in children64, the mortality rate fell to one-quarter, the rate of loss of oedema improved dramatically and the patients quickly regained their appetites. The very concept that kwashiorkor was due to protein deficiency, and that the mainstay of treatment should, therefore, be protein replacement as one would do with any other 'deficiency', seems to have maintained the high mortality rates for the past half century. It is unclear how oxidative stress causes oedema. That it can is shown by the oedema of newborn infants with vitamin E deficiency65, birds with selenium deficiency, and the oedema of pure radical injury such as exposure to ionising radiation. Subcutaneously injected dye dissipates rapidly66 as if the interstitial hyaluronate and glycose-amino-glycans were disrupted and interstitial water was in a free state. Such damage to the interstitium, with loss of the normal negative charge, if generalised.
Pergolide drug
| Fda pergolide withdrawal12.0 STATISTICAL CONSIDERATIONS 12.1 Background and Primary Endpoint The primary endpoint and basis for sample size determination will be to determine the percentage of patients who remain in CR or PR, and the percentage of patients without PD after administration of 131I-MIBG. 12.2 Sample Size Determination For the purposes of this study, a patient will be considered to have been successfully treated if that patient remains without PD for 3 years after initial administration of 131I-MIBG. Such patients will be considered to have a "successful treatment." Otherwise, the patient will be considered to have a "failed treatment and phenelzine.
Uniretic will be removed Uniretic is now available as a generic medication called from the formulary on Moexipril HCT. 7 1 2007. Oxandrin will be removed from the formulary on 7 1 2007. In response to this guidance we have removed Zelnorm from the formulary immediately, 4 1 2007. In response to this guidance we have removed Pergolide from the formulary immediately, 4 1 2007. Cosopt is now a tier 2 medication. This lower cost share status is effective immediately. Actiq will be removed from the formulary on 5 1 07. Oxandrin is now available as a generic medication called Oxandrolone. The FDA has identified potential health risks associated with Zelnorm use and has asked the manufacturer to stop marketing the product. The FDA has deemed Pergolide to be unsafe and has ordered all Pergolide to be removed from the market!
Introduction to aredia frequently asked questions about aredia aredia side effects dangerous drug topics avandia acetaminophen accutane ambien aredia baycol bextra celebrex celexa cialis crestor darvon darvocet ; depo-provera diclofenac effexor ephedra evista fluvoxamine fosamax gleevec ketek levitra lexapro meridia mirapex neurontin paxil pergolide permax ; prempro promethazine hc1 prozac risperdal seroquel serzone symbyax tamiflu tequin viagra vioxx zelnorm zoloft zometa zyprexa ortho evra patch adderall aleve dangerous drug case evaluation dangerous drug videos consumer rights defective drugs dangerous drug links dangerous drug - center for drug evaluation and research site dedicated to medicinal drugs by the food and drug administration and phenobarbital
| Patients Between July 1988 and May 1994, 144 consecutive patients under the age of 50 with newly-diagnosed AML were referred for treatment at the ICRF Department of Medical Oncology, St. Bartholomew's Hospital SBH ; and the Haematology Departments of the Ospedali Riuniti di Bergamo and Ospedale San Bortolo in Vicenza. Their clinical characteristics are shown in Table 1. The diagnosis was made according to the criteria of the French!
Pieter P. de Tombe1, Alexandra Belus2, Nicoletta Piroddi2, Beatrice Scellini2, John S Walker1, Anne F. Martin1, Chiara Tesi2, Corrado Poggesi2. Center for Cardiovascular Research, Department of Physiology and Biophysics, University of Illinois at Chicago, 2Department of Physiology, University of Florence, Florence, Italy and phenylephrine.
Pergolide and toxicity
A double blind placebo controlled trial was carried out by a European Australian group the PEARLS study ; . 100 patients with idiopathic RLS were randomised to pergolide, 0.25 to 0.75 mg, in the evening or placebo for 6 weeks in phase 1 of the study. Subsequently, patients with response on the Patient Global Impression PGI ; scale continued on double-blind pergolide or placebo, and and pergolide.
Our findings confirm safety concerns related to the use of pergolide and show that an increased risk of cardiac valvulopathy also exists in patients taking cabergoline. Taking into consideration the differences in scoring systems, the frequency of grade 3 to 4 valve regurgitation in our population 23.4% in the pergolide group and 28.6% in the and phenylpropanolamine.
34. Martensson S, Nygren J, Osheroff N, Hammarsten O. Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks. Radiat Res. 2003; 160: 291-301. Yang SW, Burgin AB Jr, Huizenga BN, Robertson CA, Yao KC, Nash HA. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci U S A. 1996; 93: 11534-11539. Larsen AK, Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta. 1998; 1400: 257-274. Xu W, Liu L, Smith GCM, Charles IG. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol. 2000; 2: 329-345. Muller C, Chistodoulopoulos G, Salles B, Panasci L. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lym.
For management of dosing when the INR is nontherapeutic, the Seventh ACCP Conference suggests that for patients with a sub-therapeutic INR, the weekly dose of warfarin be increased by 10% to 20%, and that more frequent monitoring take place until the INR is stable. For the patient with a supratherapeutic INR, preference continues for oral administration of vitamin K1 for the significantly elevated INR without major bleeding. Higher doses of oral vitamin K1 are recommended for patients with INRs 9.0 with no significant bleeding, and a new statement regarding the preferred use of oral vitamin K1 has been added and given a grade 1A recommendation. Seventh ACCP Guidelines Recommendations on the Management of the Non-Therapeutic INR For patients with INRs above the therapeutic range but 5.0 who have no significant bleeding, lower the dose or omit the dose, monitor more frequently, and resume therapy at a lower dose when the INR is in the therapeutic range. If only minimally and photofrin.
LEI develops economic expertise for government bodies and industry in the field of food, agriculture and the natural environment. By means of independent research, LEI offers its customers a solid basis for socially and strategically justifiable policy choices: carries out its research in close consultation with clients and other concerned parties within society. bases its expertise on thorough knowledge of the sector and the focused use of economic and other social scientific disciplines in this and permax.
Pergolide equine side effects
Pergolide mesylate powder
Transcranial magnetic stimulation brain, traumatic brain injury special education, zenapax induction therapy renal transplantation, plasmapheresis billing and plastic surgery 1920's. Apple polyphenols, orthopedics books, trauma center 3-10 help and tamsulosin or alfuzosin or pharmacy compounding devices.
Pergolide substitute
Petgolide, peroglide, perbolide, pergolkde, perg0lide, perfolide, pergolied, pergolid3, pefgolide, pe4golide, pergolidee, ergolide, pergollide, prrgolide, psrgolide, perggolide, pergolixe, perholide, pergolid, prgolide.
Pergolide 50 mg
Buy pergolide, pergolide for equine use, order pergolide, pergolide handling and pergolide structure. Pergolide drug, fda pergolide withdrawal, pergolide and toxicity and pergolide equine side effects or pergolide mesylate powder.
|
